Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gonzalo Fernández Hinojal"'
Autor:
Cristina Saiz-Ladera, Mariona Baliu-Piqué, Francisco J. Cimas, Aránzazu Manzano, Vanesa García-Barberán, Santiago Cabezas Camarero, Gonzalo Fernández Hinojal, Atanasio Pandiella, Balázs Győrffy, David Stewart, Juan J. Cruz-Hernández, Pedro Pérez-Segura, Alberto Ocana
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Targeting the immune system has emerged as an effective therapeutic strategy for the treatment of various tumor types, including Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-small-Cell Lung Cancer (NSCLC), and checkpoint inhibitors have show
Externí odkaz:
https://doaj.org/article/e2613e8de59843d685eb5e3e8880fef6
Autor:
Ana Alcaraz-Sanabria, Esther Cabañas Morafraile, Gonzalo Fernández-Hinojal, Guillermo Velasco, Pedro Pérez-Segura, Atanasio Pandiella, Balázs Győrffy, Alberto Ocaña
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Targeting K-RAS-mutant non-small cell lung cancer (NSCLC) with novel inhibitors has shown promising results with the recent approval of sotorasib in this indication. However, progression to this agent is expected, as it has previously been observed w
Externí odkaz:
https://doaj.org/article/9ee384c5a76f4f8eb84b7b6e6f9b72b9
Autor:
Ana, Alcaraz-Sanabria, Esther, Cabañas Morafraile, Gonzalo, Fernández-Hinojal, Guillermo, Velasco, Pedro, Pérez-Segura, Atanasio, Pandiella, Balázs, Győrffy, Alberto, Ocaña
Publikováno v:
Frontiers in immunology. 12
Targeting K-RAS-mutant non-small cell lung cancer (NSCLC) with novel inhibitors has shown promising results with the recent approval of sotorasib in this indication. However, progression to this agent is expected, as it has previously been observed w
Autor:
Balázs Győrffy, Vanesa García-Barberán, Alberto Ocaña, María Del Mar Noblejas-López, Miguel de la Hoya, José A. García-Sáenz, Igor López-Cade, Atanasio Pandiella, Pedro Pérez-Segura, Jesús Fuentes-Antrás, Ada Esteban-Sánchez, Gonzalo Fernández-Hinojal, Aránzazu Manzano
Publikováno v:
Cancers; Volume 13; Issue 16; Pages: 4118
Cancers, Vol 13, Iss 4118, p 4118 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancers
Cancers, Vol 13, Iss 4118, p 4118 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancers
© 2021 by the authors.
Alternative splicing is an essential biological process, which increases the diversity and complexity of the human transcriptome. In our study, 304 splicing pathway-related genes were evaluated in tumors from breast cance
Alternative splicing is an essential biological process, which increases the diversity and complexity of the human transcriptome. In our study, 304 splicing pathway-related genes were evaluated in tumors from breast cance
Autor:
Hugo Arasanz, Ana Isabel Bocanegra, Idoia Morilla, Joaquín Fernández-Irigoyen, Maite Martínez-Aguillo, Lucía Teijeira, Maider Garnica, Ester Blanco, Luisa Chocarro, Karina Ausin, Miren Zuazo, Gonzalo Fernández-Hinojal, Miriam Echaide, Leticia Fernández-Rubio, Sergio Piñeiro-Hermida, Pablo Ramos, Laura Mezquita, David Escors, Ruth Vera, Grazyna Kochan
Publikováno v:
Cancers; Volume 14; Issue 16; Pages: 3846
Single-agent immunotherapy has been widely accepted as frontline treatment for advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression, but most patients do not respond and the mechanisms of resistance are not well known. Several
Autor:
Luisa Chocarro, Ester Blanco, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Leticia Fernández-Rubio, Pilar Morente, Gonzalo Fernández-Hinojal, Miriam Echaide, Maider Garnica, Pablo Ramos, Ruth Vera, Grazyna Kochan, David Escors
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 10, p 5282 (2021)
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune
Externí odkaz:
https://doaj.org/article/33914f6bb11346f589343e400f8dfe06
Autor:
Miren Zuazo, Hugo Arasanz, Gonzalo Fernández‐Hinojal, Maria Jesus García‐Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, Maria Jose Lecumberri, Angela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 7, Pp n/a-n/a (2019)
Abstract The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients w
Externí odkaz:
https://doaj.org/article/3a88dbbc128d40bd80a8b975ab6348a4